Home » Stocks » RXDX

Prometheus Biosciences, Inc. (RXDX)

Prometheus Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) 1,229
Net Income (ttm) -37,138
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News
NASDAQ - 6 days ago

Prometheus Biosciences, a Phase 1 biotech developing precision antibody therapies for IBD and related diseases, filed on Friday with the SEC to raise up to $125 million in an initial public of...

SEC - 6 days ago

Prometheus Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

About RXDX

Prometheus Biosciences is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, we are developing ... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
Mark C. McKenna
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
RXDX
Full Company Profile

Financial Performance

In 2020, RXDX's revenue was $1.23 million, an increase of 9.93% compared to the previous year's $1.12 million. Losses were -$37.14 million, 24.9% more than in 2019.

Financial Statements